Large Integrated Health Outcomes Study Reveals Shifting Epidemiology In Drug Resistant Organisms
October 27 2016 - 3:25PM
A first-of-its-kind study of 900,000 hospital admissions from an
integrated health system has yielded insights into shifts in the
epidemiology of multi-drug resistant organisms (MDROs) in the
community. New research, funded by OpGen (NASDAQ:OPGN) and
conducted by Intermountain Healthcare and Enterprise Analysis
Corporation (EAC) found that Methicillin Resistant
Staphylococcus aureus (MRSA), Clostridium difficile (C. difficile)
and ESBL harboring Gram-negative rods were the most common
organisms treated by the Intermountain Healthcare system over an
eight-year period between January 1, 2008 and December 31, 2015.
The study examined data from Intermountain Healthcare over an
eight-year period to characterize the trends occurring in C.
difficile and MDROs. The abstracted electronic data was pulled from
patients seen at Intermountain’s 22 hospitals and affiliated
clinics who had clinical cultures positive for antibiotic resistant
Gram-positive or Gram-negative bacteria and/or laboratory tests
positive for toxigenic C. difficile. The researchers discovered
that resistant organisms were found in 1.4 percent of the 900,000
hospital admissions during the study period with most originating
from the ambulatory setting.
Researchers found that a 222% increase was observed in the
prevalence of C. difficile as well as a 322% increase in ESBL
positive organisms. The good news is that the prevalence of MRSA
decreased by 32%. The study measured both the prevalence of
infections, as well as impacts on patient care. Economic data are
still being analyzed and will be revealed in a future
presentation.
Results from the study were presented on Thursday, Oct. 27 at
12:30 p.m. CDT in the Poster Hall at IDWeek in New Orleans by Bert
Lopansri, M.D., lead author of the study at Intermountain Medical
Center, the flagship hospital of Intermountain Healthcare.
Highlights of the study:
- Of the 900,000 hospital admissions during the study period,
12,905 (1.4%) were from patients positive for an MDRO and/or C.
difficile.
- While MRSA continues to be the most common MDRO, rates have
declined.
- MRSA, ESBL and CRE forms of E. coli were less frequently
acquired in the hospital while VRE, multi-drug resistant
Pseudomonas, and other CRE’s were more frequently encountered in a
healthcare setting.
- 70% of all MDROs and C. difficile cases originated from an
ambulatory setting.
- While all-cause, in hospital mortality was relatively low (7%),
significantly more patients with MDRO require continued medical
care in some capacity.
“For the last 10 to 15 years, the number of antibiotic-resistant
bacteria continues to increase. We wanted to turn on the lights and
look at all the different types of antibiotic-resistant bacteria
that have been highlighted as serious and urgent threats by the
Centers for Disease Control to see what the landscape looks like in
our system,” said Dr. Lopansri, Chief of the Infectious Diseases
Division at Intermountain Medical Center. “Although MRSA still
poses the greatest challenge, the rise in ESBLs is a major concern
and mirrors findings reported at other centers in the U.S.,” added
Dr. Lopansri. “One concern with ESBLs is that the most common
antibiotic used to treat them are carbapenems, known as
‘last-resort’ antibiotics.”
“Our support for a study of this magnitude provides a benchmark
to hospitals and health systems on what could be lurking in their
facilities as we seek to validate the health and economic impact of
our rapid MDRO products and services to improve infection control,”
said Evan Jones, Chairman and CEO of OpGen. “The next step in this
collaboration will revolve around leveraging our technologies to
guide rapid clinical decisions with a goal of reducing the spread
of these infections and improving health outcomes.”
In addition to presenting these study results, Dr. Lopansri will
be hosting a discussion of the study and its results at the
Learning Lounge. The discussion is titled, “Antibiotic resistant
bacteria in our Integrated Healthcare Network: are new diagnostic
tests needed?” and will take place on Saturday, October 29, 2016
from 1:15 p.m. to 1:45 p.m. CDT at booth #1300.
About Intermountain Healthcare Intermountain
Healthcare is a Utah-based, not-for-profit system of 22 hospitals,
185 clinics, a Medical Group with about 1,500 employed physicians
and advanced practitioners, a health plans group called
SelectHealth, and other health services. With a mission of helping
people live the healthiest lives possible®, Intermountain is widely
recognized as a leader in transforming healthcare through high
quality and sustainable costs.
About OpGenOpGen, Inc. is harnessing the power
of informatics and genomic analysis to provide complete solutions
for patient, hospital and network-wide infection prevention and
treatment. Learn more at www.opgen.com and follow OpGen on Twitter
and LinkedIn.
OpGen Contact:
Michael Farmer
Director, Marketing
(240) 813-1284
mfarmer@opgen.com
InvestorRelations@opgen.com
OpGen Investor and Media Contact:
MacDougall Biomedical Communications
Cammy Duong
781-235-3060
cduong@macbiocom.com
Intermountain Healthcare Contact:
Jess C. Gomez
Director of Media Relations
801-718-8495
jess.gomez@imail.org
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Jul 2024 to Aug 2024
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Aug 2023 to Aug 2024